Inogen (NASDAQ:INGN) EVP Sells $72,190.80 in Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,938 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This trade represents a 68.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Inogen Trading Down 0.8%

Shares of Inogen stock opened at $6.49 on Thursday. The stock has a market capitalization of $175.75 million, a price-to-earnings ratio of -7.13 and a beta of 1.58. The firm’s 50-day moving average price is $6.57 and its two-hundred day moving average price is $6.41. Inogen, Inc has a 1-year low of $5.34 and a 1-year high of $9.13.

Inogen (NASDAQ:INGN) last announced its earnings results on Thursday, May 7th. The medical technology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The business had revenue of $85.11 million during the quarter, compared to analyst estimates of $82.35 million. Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%. As a group, equities research analysts predict that Inogen, Inc will post -0.77 EPS for the current year.

Institutional Investors Weigh In On Inogen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Alliancebernstein L.P. raised its stake in shares of Inogen by 3.9% during the third quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock worth $418,000 after buying an additional 1,900 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Inogen by 14.6% during the 4th quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock valued at $131,000 after acquiring an additional 2,487 shares during the last quarter. Rhumbline Advisers raised its position in shares of Inogen by 7.0% during the 2nd quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 2,561 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Inogen by 4.9% in the 2nd quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock valued at $431,000 after purchasing an additional 2,858 shares during the period. Finally, Barclays PLC lifted its stake in shares of Inogen by 4.5% in the 4th quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock valued at $551,000 after purchasing an additional 3,515 shares during the period. 89.94% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on INGN. Freedom Capital upgraded Inogen to a “strong-buy” rating in a report on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.